<DOC>
	<DOCNO>NCT00780052</DOCNO>
	<brief_summary>The purpose study evaluate whether C-myb Antisense ( AS ) Oligonucleotides ( ODNs ) possible treatment modality advance hematologic malignancy .</brief_summary>
	<brief_title>Infusional C-myb ASODN Advanced Hematologic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Patients must one following : acute myeloid lymphoid leukemia ; Myeloproliferative disorder ( MPD ) include Chronic Myelogenous Leukemia ( CML ) ; Myelodysplastic Syndrome ( MDS ) ; NonHodgkin 's Lymphoma ( include CLL ) ; Multiple Myeloma Patients acute leukemia must meet one follow condition : *have disease refractory course standard induction chemotherapy *have relapse diseased documentation previous clinical remission *have untreated disease candidate conventional first line treatment Patients CML MPD must evidence accelerate phase blast crisis Patients clinical feature CML transformation negative Philadelphia chromosome may enter provide prior definable chronic phase Patients Philadelphia chromosome positive CML must fail treated Gleevec ( Imatinib ) order eligible study Patients myelodysplastic syndrome ( MDS ) must &gt; 5 % blast peripheral blood bone marrow diagnosis IPSS score &gt; = 1 Patients CLL must relapse refractory disease least three course conventional therapy determine long candidate conventional therapy Patients nonHodgkin 's lymphoma ( CLL ) must relapse refractory disease least two course chemotherapy determined candidate conventional therapy Patients multiple myeloma must fail least 3 prior therapy Performance Status 0 , 1 2 Serum creatinine &lt; 2.0 mg/dl ; serum bilirubin &lt; 2 mg/dl AST/ALT &lt; 3.0 x upper limit normal PTT within normal range Age &gt; 18 Patients must indwell central venous catheter Significant cardiac disease require active therapy Intercurrent organ damage medical problem jeopardize outcome therapy Pregnant lactating female Received prior cmyb AS ODN therapy Patients suitable HLA identical sibling donor deem appropriate willing candidate allogeneic bone marrow transplantation Patients require anticoagulation unfractionated heparin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Hematologic Malignancies</keyword>
	<keyword>c-myb</keyword>
	<keyword>c-myb AS ODN</keyword>
</DOC>